Wegovy Pill Wins EU Approval, Yet Novo Nordisk’s Rally Faces a Jittery Wait for FDA and Earnings
The European Commission has handed Novo Nordisk a clear edge in the race to dominate the oral weight?loss…
Novo Nordisk: Court Victory and Pill Approval Propel Recovery, Yet 2026 Revenue Slump Casts a Shadow
Novo Nordisk has been handed a series of catalysts in quick succession — a landmark patent ruling in…
Novo Nordisk’s Semaglutide Data Piles Up, Yet Stock Remains Unmoved
Novo Nordisk reveals new semaglutide data at ADA, including longevity and aesthetic potential, but shares remain under pressure—down…
European Lithium Clears Cash Hurdle for Critical Metals Merger, Yet ASX Suspension and Greenland Per
European Lithium shares trade at 40% discount to merger implied value despite meeting A$330M cash condition, as ASX…
Novo Nordisk’s Oral Wegovy Outpaces Eli Lilly Fivefold, Yet Jefferies Stays on the Sidelines
Novo Nordisk’s oral Wegovy pill notches 18,410 new US scripts in launch week, five times Eli Lilly’s Foundayo.…
Oral Wegovy Wins EMA Panel Backing, Yet Novo Nordisk Shares Remain Under Pressure
EMA recommends first oral GLP-1 obesity pill for EU approval, but Novo Nordisk shares tumble 15% YTD amid…
Novo Nordisk’s High-Dose Shot and Amazon Push Provide Lift, Yet Stock Sags on Generics and FDA Rev
Despite strong weight-loss data and an Amazon Pharmacy deal, Novo Nordisk shares slump on patent cliff fears, FDA…
Novo Nordisk’s Oral GLP-1 Launch Beats Forecasts, Yet India Price War and Market Caution Check Ent
Novo Nordisk’s oral Wegovy crushes Q1 forecasts with $2.26B revenue, yet a fast-maturing India generics threat and CagriSema…